#USA #San Francisco #J.P. Morgan #Viking Therapeutics #VKTX

Viking Therapeutics to Present at J.P. Morgan Healthcare Conference

Viking Therapeutics, Inc., a biopharmaceutical company in the clinical stage, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The event is set to take place from January 12-15, 2026, in San Francisco, California. This year, Dr. Brian Lian, the CEO of Viking, will deliver a significant corporate presentation that outlines the company's latest advancements in therapies for metabolic and endocrine disorders.

Conference Details

The presentation is scheduled for January 12, 2026, at 2:15 PM - 2:55 PM Pacific Time. Attendees will have the opportunity to learn about Viking's innovative approach to developing therapies designed to enhance patient well-being. The presentation will also include one-on-one meetings, allowing for in-depth discussions regarding Viking’s pipeline and future directions.

A live webcast of the presentation will be streamed on the Viking Therapeutics website, under the Investors & Media section. Additionally, a recording of the event will be accessible after the conference, making it a valuable resource for those unable to attend.

About Viking Therapeutics

Viking Therapeutics specializes in the development of novel therapies aimed at treating metabolic and endocrine disorders. The company’s research strategy focuses on harnessing its expertise in metabolism to create groundbreaking therapeutics that significantly improve patient quality of life. Among Viking's promising clinical programs is VK2735, an innovative dual agonist targeting glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This therapeutic candidate aims to address various metabolic disorders and is currently being evaluated in a Phase 3 program that includes two pivotal trials: VANQUISH-1 and VANQUISH-2.

Preliminary results from earlier Phase 1 and Phase 2 trials of VK2735 have shown a favorable safety and tolerability profile, coupled with early indicators of clinical benefits. The company is also exploring an oral formulation of VK2735 specifically for obesity treatment.

In addition to VK2735, Viking is advancing VK2809, an oral small molecule designed to selectively target thyroid hormone receptor beta, aimed at treating both lipid and metabolic disorders. The drug has shown promising results, achieving primary and secondary endpoints in a Phase 2b study for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In another Phase 2a trial focused on non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, significant reductions in detrimental lipid levels were noted among participants treated with VK2809 compared to those receiving a placebo.

Viking's latest research efforts are directed towards a new class of compounds: dual amylin and calcitonin receptor agonists (DACRAs), designed to tackle obesity and related metabolic issues. Moreover, in the rare disease segment, the company is developing VK0214, an orally active small molecule selective for thyroid hormone receptor beta, targeting X-linked adrenoleukodystrophy (X-ALD). Initial findings from a Phase 1b clinical trial suggest VK0214 is safe, well-tolerated, and effectively reduces plasma levels of very long-chain fatty acids, significantly benefiting patients with the adrenomyeloneuropathy form of X-ALD.

Through these innovative programs, Viking Therapeutics aims to make a meaningful impact on the lives of patients suffering from metabolic and endocrine conditions. For further insights into their groundbreaking research and therapeutic developments, visit Viking Therapeutics.

Conclusion

The J.P. Morgan Healthcare Conference presents an excellent platform for Viking Therapeutics to share its visionary drug development strategies with the healthcare community. As they prepare for the conference, anticipation builds around the unveiling of their latest innovations and clinical findings that hold the promise of revolutionary treatments in metabolic and endocrine disorders.